Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Early detection of molecular relapse with ctDNA tracking and treatment with palbociclib plus fulvestrant in ER-positive HER2-negative breast cancer

Phase 2 trial of ctDNA surveillance and, in the treatment phase, palbociclib plus fulvestrant versus standard endocrine therapy. Registry primary outcomes include the incidence of a positive ctDNA result and relapse-free survival. ClinicalTrials.gov lists the study as recruiting.

Royal Marsden NHS Foundation Trust